Long guide RNA purifications are persistently challenging for the gene editing industry. Development of analytical standard protocols is painfully lagged. The routinely reported HPLC purities are misleadingly overestimated to be much higher than the full-length-product contents, posing catastrophic off-target risks for the patients. GeneLancet has issued CRISPR guide RNA white paper, titled as “Addressing sgRNA Truncated Impurities in CRISPR Therapeutics and sgRNA Poor Scalability with Chemically Ligated Guide RNAs (LgRNA)”.
GeneLancet guide RNA white paper
